Zydus Cadila has received final approval from the USFDA to market Solifenacin Succinate Tablets, (US RLD: Vesicare® Tablets) in the strengths of 5 mg and 10 mg. Solifenacin Succinate is a symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with overactive bladder syndrome.
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad.
The group now has 309 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.422.5 as compared to the previous close of Rs. 430.55. The total number of shares traded during the day was 121149 in over 3064 trades.
The stock hit an intraday high of Rs. 437 and intraday low of 419.7. The net turnover during the day was Rs. 51558696.